Antheia Receives Conditional $80 Million Loan Commitment from U.S. Department of War to Support Domestic Pharmaceutical Manufacturing
Antheia has received a conditional commitment for an up to $80 million long-term loan from the Office of Strategic Capital (OSC) under the U.S. Department of War. The funding aims to support Antheia's strategy to onshore critical pharmaceutical ingredient production, addressing vulnerabilities in supply chains that currently rely heavily on foreign sources. The company emphasizes how this move will enhance public health and national security by reducing dependence on overseas suppliers for key starting materials (KSMs) and active pharmaceutical ingredients (APIs). This conditional financing is part of broader efforts to build resilient domestic manufacturing capabilities, with Antheia having already secured $32 million in non-dilutive federal funding. Antheia's biosynthesis platform has been recognized as a priority technology for strengthening public health systems. The loan would provide the company flexibility during its next phase of commercial growth and help expand U.S.-based manufacturing capacity, aligning with national priorities to secure critical supply chains.
Topics: Government Funding Pharmaceuticals Supply Chain Resilience